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Summary
Obesity is associated with chronic low-grade inflammation that affects the pheno-
type of multiple tissues and therefore is implicated in the development and progres-
sion of several age-related chronic inflammatory disorders. Importantly, a new family
of noncoding RNAs, termed long noncoding RNAs (lncRNAs), have been identified as
key regulators of inflammatory signalling pathways that can mediate both
pretranscriptional and posttranscriptional gene regulation. Furthermore, several
lncRNAs have been identified, which are differentially expressed in multiple tissue
types in individuals who are obese or in preclinical models of obesity. In this review,
we examine the evidence for the role of several of the most well-studied lncRNAs in
the regulation of inflammatory pathways associated with obesity. We highlight the
evidence for their differential expression in the obese state and in age-related condi-
tions including insulin resistance, type 2 diabetes (T2D), sarcopenia, osteoarthritis
and rheumatoid arthritis, where obesity plays a significant role. Determining the
expression and functional role of lncRNAs in mediating obesity-associated chronic
inflammation will advance our understanding of the epigenetic regulatory pathways
that underlie age-related inflammatory diseases and may also ultimately identify new
targets for therapeutic intervention.
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1 | INTRODUCTION
With the understanding that much of the human genome is tran-
scribed into noncoding transcripts, it comes as no surprise that long
noncoding RNAs (lncRNAs) have been linked to multiple diseases
including developmental disorders and many cancers. Characterized
as noncoding transcripts larger than 200 nucleotides,1 they are the
largest and most heterogeneous group of noncoding RNAs involved in
several cellular processes.2,3 Generally transcribed by RNA polymer-
ase II, lncRNA transcripts undergo splicing events to remove introns
and form alternatively spliced isoforms, are 50 capped and can even be
polyadenylated. LncRNAs can exhibit tissue and cell-specific expres-
sion4,5 and can impact gene regulation at every level, from manipulat-
ing epigenetic marks and chromatin folding to transcriptional
initiation, activation and silencing, RNA splicing, editing, translation
and RNA and protein turnover.6
The LncRNA and Disease Database (LncRNADisease: http://
www.cuilab.cn/lncrnadisease) has seen entries surge from 63 disease-
associated lncRNAs to 2,947 experimentally verified disease-
associated lncRNAs in as little as 5 years.7 With the development in
deep-sequencing technologies, studies have been able to uncover
genome-wide mutations associated with disease. Remarkably, Calin
et al. found that many ultra-conserved noncoding regions that give
rise to ncRNAs harbour mutations in cancers that lead to their dys-
regulation.8,9 Currently, the function and mechanism of action of the
vast majority of lncRNAs remain unclear. However, there are a small
number of well-characterized lncRNAs, which have provided evidence
of several mechanisms by which lncRNAs can exert their diverse func-
tions. A strong argument for the physiological importance of lncRNAs
as molecular signals lies in their variable expression observed between
different cell types and tissues, in response to numerous stimuli and
timely expression at specific developmental cues.10 The process of ini-
tiation, elongation or termination at a lncRNA gene alone can suffice
to elicit a regulatory response.10 Additionally, transcripts are thought
to recruit chromatin-remodelling complexes to modulate epigenetic
regulation leading to either the repression or activation of specific
genes. This holds true in the case of the X-inactive specific transcript
(XIST), the antisense of insulin growth factor 2 receptor lncRNA and
HOX transcript antisense RNA (HOTAIR) known to interact with sev-
eral histone-modifying complexes. XIST is thought to recruit the PRC2
complex, which is essential for catalysing the repressive histone modi-
fication, trimethylation of histone H3 lysine 27 (H3K27me3), leading
to X-chromosome inactivation.11 As such, XIST influences chromatin
compaction and silencing of the future inactive X-chromosome. Simi-
larly, HOTAIR is also known to selectively bind components of the
PRC2 complex including the histone methyltransferase EZH2.12
Whereas the 50 region of HOTAIR associates with PRC2 proteins, the
30 domain also has been found to interact with the histone
demethylase complex LSD1/CoREST/REST.13
Decoy lncRNAs can act as a sponge or ‘molecular sink’ for RNA-
binding proteins or as guides to specifically localize bound proteins to
target genes, allowing for greater coordination of transcription factors
and chromatin modifiers (Figure 1A,B).10 GAS5 is a well-studied decoy
lncRNA that competitively binds the DNA-binding domain of the glu-
cocorticoid receptor (GR) supressing the activation of GR target genes
(Figure 1A),14 whereas MEG3 lncRNA acts as a guide for the PRC2
complex to specific chromatin sites due to a triplex forming GA-rich
sequence at MEG3 binding sites that enable an RNA–DNA triplex for-
mation (Figure 1B).15 Similarly, CCDC26 lncRNA regulates global
DNA methylation in myeloid cells by coordinating the subcellular loca-
tions of DNA-methyltransferase 1 (DNMT1).16 LncRNAs can also act
as scaffolds forming functional ribonucleoprotein complexes providing
a platform for the assembly of multiple proteins onto chromatin
through sequence complementarity, stem loops, affinity and various
tertiary structures (Figure 1C,D).17 HOTAIR is cited as such owing to
its ability to simultaneously bind the PRC2 and LSD1 complex bridging
the two to form the gene suppressive HOTAIR/PRC2/LSD1 complex
(Figure 1C).10,18 Similarly, lncRNA ROCKI forms a ribonucleic complex
at the MARCKS promoter with the endodeoxyribonuclease APEX1,
which recruits HDAC1, a histone deacetylase to silence its own tran-
scription (Figure 1D).19 These are the key mechanisms by which
lncRNAs can epigenetically influence chromatin state and gene regula-
tion. As such, lncRNAs are directly and indirectly significant for coor-
dinating the activation or repression of target genes, and thus, it is
important to gain an understanding of these integral regulators in the
context of obesity-associated chronic inflammation on age-related
conditions (Table 1).
2 | LncRNAs AND OBESITY
Obesity is the accumulation of excessive body fat, which can severely
impact health and currently affects 650 million adults worldwide.
Transcriptional analyses by both next-generation sequencing and
microarray have identified several lncRNAs that are differentially
expressed in body fat or adipose tissue (AT) in individuals who are
obese. The human body consists of the insulating, energy-storing
white AT (WAT) and thermogenic brown AT (BAT). Visceral WAT
around the intra-abdominal organs and subcutaneous WAT under the
skin are fundamental in energy homeostasis, whereas energy-burning
and heat-generating BAT is found around the shoulders and ribs.20 In
obesity, BAT undergoes molecular and morphological changes effec-
tively ‘whitening’ to resemble WAT, thus impacting on metabolic dys-
function and inflammation.21 Brown fat lncRNA 1 (Blnc1) is a
conserved BAT-enriched nuclear lncRNA that acts as a scaffold to
form ribonucleoprotein complexes with several transcription factors.
In BAT, Blnc1 interacts with thermogenic transcription factors includ-
ing EBF2 and ZBTB7B.21–23 Zhao et al. found high expression of
Blnc1 in high-fat diet (HFD)-fed obese mice, which on conditional
inactivation accelerated BAT whitening, fibrosis and tissue inflamma-
tion.21 Transgenic expression of Blnc1 rescues these effects by silenc-
ing pro-inflammatory cytokines interleukin 6 (IL-6) and CCL5 and
promoting lipid metabolism through a ribonucleoprotein complex with
ZBTB7B.21 Additionally, Tang et al. find that not only is over-
expression of Blnc1 in WAT protective against HFD-induced obesity
but through remodelling of mitochondrial biogenesis is able to
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improve insulin sensitivity.24 There is increasing interest in the lipid
oxidation-mediated thermoregulatory properties of BAT, and under-
standing the role of lncRNAs in this process may be key in harnessing
this potential for therapeutic treatment of obesity.20,24
RNA-sequencing analysis of human AT has provided a catalogue
of over 3,000 lncRNAs, of which approximately 900 were specifically
detected in BAT, which in humans is associated with improved meta-
bolic health. Of these BAT-specific lncRNAs, the expression of lnc-
dPRM16 was associated with the expression of BAT-selected markers
in vivo and its knockdown impaired differentiation of brown adipo-
cytes.25 Furthermore, BAT H19 expression, which in the mouse
decreases with obesity, has been reported to be inversely correlated
with body mass index (BMI) in humans.26 H19 is implicated in several
obesity-associated inflammatory conditions. H19 expression is
reduced in adipocytes from individuals with obesity, and its over-
expression in mice was found to have a protective effect against diet-
induced obesity and improved insulin sensitivity in BAT but not WAT
tissue.26 As BAT ‘whitening’ in obesity impacts on metabolic dysfunc-
tion and inflammation,21 there is increasing interest in the
thermoregulatory properties of BAT, and understanding the role of
lncRNAs may be key in tackling obesity and obesity-associated
conditions.
In abdominal subcutaneous WAT, 1,268 lncRNAs were found to
be differentially expressed in children with obesity, compared with
age- and gender-matched children without obesity. Of these, the
expression level of lncRNA RP11-20G13.3 was positively associated
with BMI, waist circumference, waist-to-hip ratio, fasting insulin, low-
density lipoprotein cholesterol, high-sensitivity C-reactive protein and
leptin. On the contrary, the expression level of the lncRNA GYG2P1
was negatively associated with BMI, waist circumference, fasting insu-
lin and triglycerides.27 In a separate study, lncRNA u001kfc.1 was
identified as differentially downregulated in visceral WAT from indi-
viduals with obesity, compared with those without,28 and was
predicted to be a potential cis-regulator for phosphatase and tensin or
PTEN homolog.
In addition to AT, differential expression of lncRNAs has been
reported in the blood of individuals classed as obese, suggesting that
the obesity-associated differences in lncRNA expression will affect
F IGURE 1 LncRNA mechanisms of action. (A) Decoy: by binding the glucocorticoid receptor (GR), GAS5lncRNA prevents GR from binding its
DNA target. (B) Guide: RNA-binding PRC2 complex is directed to specific targets through interactions with specific lncRNAs such as MEG3.
(C) Scaffold: HOTAIR lncRNA acting as a scaffold brings together groups of proteins (PRC2 and LDS1 complexes), which may otherwise not be
able to interact and work together as part of a ribonucleoprotein complex. (D) Scaffold lncRNAs like ROCKI can also interact with DNA at specific
promoters; in this case, ROCKI binds its own promoter, allowing for the assembly of chromatin-modifying ribonucleoprotein complexes to
activate the downstream gene by changing the epigenetic marks at the promoter. The figure is not to scale. LncRNA examples are discussed in
detail in Section 1. HOTAIR, HOX transcript antisense RNA; lncRNA, long noncoding RNA; ROCKI, Regulatory of Cytokines and Inflammation
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TABLE 1 Summary of lncRNAs and associated conditions
Disease/biological process LncRNA Mechanism Reference
Adiposity GYG2P1 Expression is negatively associated with BMI,
waist circumference, fasting insulin and
triglycerides.
Liu et al.27
lnc-dPrm16 Loss of function markedly represses brown
adipogenesis whereas in WAT results in
reduced expression of pan-adipogenic
markers and BAT-selective markers. Also





LncRNA expression is negatively correlated
with BMI, waist circumference, waist-to-hip
ratio and fasting insulin.
Sun et al.29
lncRNA-p5549 LncRNA expression is negatively correlated
with BMI, waist circumference, waist-to-hip
ratio and fasting insulin.
Sun et al.29
MIST Knockdown in adipose tissue macrophages
increases M1-associated genes, whereas
gain of function reduces genes associated
with inflammation and lipid metabolism.
Epigenetically regulates pro-inflammatory
genes through an interaction with PARP1.
Stapleton et al.63
RP11-20G13.3 Knockdown prevents adipocyte differentiation
and reduces the mRNA levels of PPARγ,
C/EBPα and adiponectin during adipocyte
differentiation.
Liu et al.27
Diabetes ANRIL Methylation of ANRIL promoter is reduced in
subcutaneous adipose; ANRIL expression is
induced by high glucose and diabetes and is
positively correlated with pro-inflammatory
factors. ANRIL is also transcriptionally
regulated by NF-κB-meditated TNFα.
Lillycrop et al.,52 Thomas et al.,55 and
Zhou et al.56
H19 Decreased in muscle of individuals with
obesity and type 2 diabetes resulting in
impaired insulin signalling and decreased
glucose uptake through the PI3K/AKT
pathway induced by Let-7 miRNA.
Gao et al.64
Insulin resistance ASMER1 Expression correlated with increased lipid
metabolism. Silencing reduces adiponectin
release, impacts lipolysis, fatty acid and
energy metabolism leading to reduced
triglyceride accumulation.
Gao et al.45
ASMER2 Expression correlated with inflammatory
pathways. Silencing reduces adiponectin
release, impacts lipolysis, fatty acid and
energy metabolism leading to reduced
triglyceride accumulation.
Gao et al.45
MIST MIST expression in human adipose tissue
macrophages is downregulated in
individuals with obesity and negatively
correlated with insulin resistance. This





Negatively associated with insulin resistance
and upregulated by 12-week diet-induced
weight loss.
Sun et al.29
Blnc1 Transgenic expression silences pro-
inflammatory cytokines and promotes lipid
metabolism, whereas silencing accelerated
Zhao et al.21 and Tang et al.24
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TABLE 1 (Continued)
Disease/biological process LncRNA Mechanism Reference
BAT fibrosis and tissue inflammation.
Overexpression in WAT is protective
against HFD-induced obesity and improves
insulin sensitivity.
H19 H19 expression reduces with adiposity.
Overexpression in mice has a protective
effect against diet-induced obesity and
improves insulin sensitivity in BAT. H19
recruits PEG-inactivating H19-MBD1
complexes and acts as BAT-selective PEG
gatekeeper.
Schmidt et al.26
LncASIR Silencing downregulates metabolic pathways
downstream of insulin signalling including
PPAR and adipocytokine signalling.
Degirmenci et al.57
SRA1 Overexpression increases insulin-stimulated
uptake of glucose and represses pro-
inflammatory chemokine CCL2; however,
SRA−/− mice are protected from diet-
induced obesity, are more sensitive to
insulin and are less inflammatory with
reduced expression of TNFα, CCL2 and IL-6.
Xu et al.49 and Liu et al.50
u001kfc.1 Downregulated in WAT of individuals with
obesity and associated with enhanced
insulin sensitivity in WAT by cis-regulating
PTEN.
Yang et al.28
Myogenesis H19 Promotes myoblast differentiation by
suppression of Sirt1/FOXO1 expression.
Also, increases miR-675-3p and miR-
675-5p, in turn suppressing BMP/TGF-β
signalling.
Dey et al.78
MALAT1 Evidence of both promoting myogenesis via
upregulation of muscle specific gene
expression and suppressing myogenesis by
inhibiting MyoD.
Chen et al.82
Osteoarthritis MALAT1 Knockdown reduces proliferation of obese
OASF and expression of IL-6 and CXCL8.
Nanus et al.98
Rheumatoid arthritis MALAT1 Silencing results in an increase in IL-6, IL-10
and TNFα secretion and elevated
proliferation. MALAT1 binds to the
promoter of CTNNB1 regulating DNA





H19 Serum starvation and stimulation with or
without IL-1β, TNFα or PDGF-BB induce
H19 expression in synovial fibroblasts via
the MAP-kinase ERK-1/2 and
phosphatidylinositol-3 kinase pathways.
Pearson et al.100
HOTAIR Exosomal HOTAIR contributes to the
migration and activation of macrophages as
well as the production of MMPs in
individuals with obesity.
Lu et al.112 and Song et al.113
Skeletal muscle atrophy Atrolnc1 Binds and represses ABIN1, an endogenous
inhibitor of NF-κB, in turn facilitating
increased NF-κB-mediated transcription of
the ubiquitin E3 ligase MuRF-1
Sun et al.87
Chronos Represses Bmp7, a positive regulator of
hypertrophic gene expression. Increased
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distal tissues. With the use of an lncRNA array, a total of 249 lncRNAs
were found to be differentially expressed (213 upregulated and
36 downregulated) in the blood of those individuals with obesity,
compared with healthy control individuals. Of these, the circulatory
expression of three lnRNAs, namely, lncRNA-p5549, lncRNA-p21015
and lncRNA-p19461, was negatively correlated with BMI, waist cir-
cumference, waist-to-hip ratio and fasting insulin.29 Furthermore, the
circulatory expression of lncRNA-p19461 was significantly increased
in eight individuals with obesity following a 12-week diet-induced
weight loss programme.29 These findings support the notion that the
effect of obesity on lncRNA expression may extend to peripheral tis-
sues with implications for age-related conditions influenced by
obesity-associated chronic inflammation.
3 | LncRNAs AND OBESITY-ASSOCIATED
CHRONIC INFLAMMATORY DISEASE
Obesity-associated chronic inflammation largely features the energy-
storing endocrine organ AT. AT is not only recognized for its endo-
crine role in regulating energy homeostasis but also in the regulation
of immunity and inflammation.30 AT is largely composed of fat cells
known as adipocytes, which store energy as fat. Increased adiposity
directly impacts AT remodelling as adipocytes overaccumulate to
accommodate an increased demand for lipid storage. This can have
severe effects on lipogenesis, lipolysis and AT adipokine responses
leading to metabolic stress, adipocyte cell death and hypoxia. These
events culminate in the activation of JNK and NF-κB signalling path-
ways, which regulate the production and release of pro-inflammatory
signalling molecules known as cytokines, contributing to an inflamma-
tory AT microenvironment and their accumulation in multiple tissues
including skeletal muscle.30–32 LncRNAs are now being recognized as
contributing intermediates in obesity and inflammation, although the
exact molecular processes involving lncRNAs in obesity-associated
inflammatory conditions is still unclear. Here, with the focus on
obesity-associated chronic inflammatory diseases, this section will
highlight the fundamental lncRNAs involved in AT remodelling and
those that may contribute to obesity-associated inflammation.
3.1 | Insulin resistance and type 2 diabetes
(mellitus)
Obesity-linked insulin resistance leads to increased lipolysis, elevated
plasma fatty acid levels and reduced tissue glucose transport, which,
coupled with simultaneous dysfunction of pancreatic β-cells, may
result in the development of type 2 diabetes (T2D).33 AT becomes less
responsive to insulin during obesity as adipocytes become enlarged
(hypertrophic) and more inflammatory. However, the mechanism
linking insulin resistance to inflammation remain unclear. There is
evidence that low-grade inflammation may play a role in the
development of insulin resistance and pathogenesis of T2D and its
co-morbidities,34,35 but a reverse causation has also been suggested
whereby insulin resistance and dysregulation of metabolic control can
lead to low-grade inflammation and contribute to pancreatic β-cell
dysfunction, and hence glycaemic control, in T2D.36,37 However, the
use of anti-inflammatory compounds (salicylic acid, salsalate and spe-
cific antagonists against pro-inflammatory molecules such as IL-1 and
TNFα) as potential antidiabetic treatments in human clinical trials has
produced small or modest fasting glucose and HbA1c-lowering
effects, which were a consequence of improved β-cell function (possi-
bly as a result of a decrease in islet inflammation), but had no effect
on peripheral insulin resistance.38–44 As such, lncRNAs are now gath-
ering interest as potential alternative therapeutic targets.
Gao et al. identified 86 differentially expressed lncRNAs between
obese and nonobese individuals and 44 lncRNAs that were differen-
tially expressed in individuals who were insulin resistant versus insulin
sensitive and obese.45 The adipocyte-specific metabolic-related
lncRNAs, ASMER-1 and ASMER-2, were identified in RNA sequencing
and microarray analysis of human WAT from 108 female participants
with obesity and insulin sensitivity. Bioinformatics analysis revealed
that ASMER-1 increased lipid metabolism whereas ASMER-2 expres-
sion correlated with inflammatory pathways.45 Silencing of both
ASMER-lncRNAs resulted in reduced adiponectin release and
impacted lipolysis, fatty acid and energy metabolism leading to
reduced triglyceride accumulation.45,46 Adiponectin has a role in insu-
lin sensitizing and is found to be reduced in obesity-linked insulin
resistance.47 An interesting therapeutic strategy for obesity-
TABLE 1 (Continued)
Disease/biological process LncRNA Mechanism Reference
MAR1 Acts as a sponge for mir-487b in C2C12 cells,
in turn preventing a reduction in Wnt5a
expression, promoting myogenesis.
Expression decreases with age and muscle
unloading in mice.
Zhang et al.85
Abbreviations: AKT, protein kinase B; ANRIL, antisense noncoding RNA in the INK4 locus; ASMER, adipocyte-specific metabolic-related lncRNAs;
Atrolnc-1, atrophy-related long noncoding RNA-1; BAT, brown adipose tissue; Blnc1, brown fat lncRNA 1; BMI, body mass index; C/EBP, CCAAT-
enhancer binding protein; CCL2, C–C motif chemokine ligand 2; Chronos, Gm17281; FOXO, forkhead box o; HFD, high-fat diet; HOTAIR, HOX transcript
antisense RNA; IL-1β, interleukin 1-beta; IL-6, interleukin 6; lncASIR, adipose-specific insulin responsive lncRNAs; lnc-dPRM16, long noncoding RNA diver-
gent from PR domain containing 16; lncRNA, long noncoding RNA; MALAT1, metastasis associated lung adenocarcinoma transcript 1; MAR1, muscle ana-
bolic regulator 1; miRNA, microRNA; MIS, macrophage inflammation-suppressing transcript; NF-κB; OASF, osteoarthritis synovial fibroblasts; PI3K,
phosphatidylinositol-3 kinase; PPAR, peroxisome proliferator-activated receptor; SRA1, steroid receptor RNA activator 1; TNFα, tumour necrosis factor
alpha; WAT, white adipose tissue.
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associated insulin resistance has involved increasing expression of
adiponectin and its receptors.47 Further work is required to fully
understand the mechanisms by which these ASMER-lncRNAs impact
upon adiponectin, and it remains yet to be seen whether these may
have a therapeutic potential in obesity and insulin resistance.
The steroid receptor RNA activator 1 (SRA1) was the first steroid
receptor coactivator lncRNA discovered over 20 years ago.48 The
SRA1 gene is transcribed into four transcripts, two protein-coding and
two noncoding transcripts including an intergenic lncRNA. The inter-
genic lncRNA SRA1 is highly expressed in WAT and is reported to
promote adipocyte differentiation. SRA1 binding of the adipogenic
master transcriptional regulator, PPARγ, enhances its transcriptional
activity and upregulates the expression of several adipocyte genes
including key adipogenesis regulators, such as C/EBPα, and PPARγ
itself.49,50 Overexpression of the SRA1 gene upregulated genes
involved in insulin-related signal transduction pathways as well as
inflammation. in vitro analysis of glucose uptake found that SRA1
overexpression resulted in increased insulin-stimulated uptake of glu-
cose. This was consistent with phosphorylation of protein kinase B
(AKT) and FOXO1. Additionally, Xu et al. found that inflammatory
genes where strongly repressed upon SRA1 overexpression including
the macrophage-attracting chemokine CCL2. Further investigation
confirmed that SRA1 knockdown, with short-hairpin RNAs, had the
opposite effect to overexpression, including inhibition of AKT and
FOXO2 phosphorylation, inhibition of glucose uptake and
upregulation of tumour necrosis factor alpha (TNFα)-induced JNK
phosphorylation.49 Together, these data suggest both anti-
inflammatory and insulin sensitivity-enhancing properties of SRA1.
More recently, the Xu group found that HFD-fed mice highly
expressed the SRA1 gene in WAT and generated a SRA1 gene knock-
out mice (SRA−/−) with a lean phenotype.50 In contrast to their previ-
ous study, SRA−/− mice protected from diet-induced obesity were
more sensitive to insulin and less inflammatory with reduced expres-
sion of TNFα, CCL2 and IL-6. There are number of discrepancies
between these two studies regarding insulin sensitivity and whether
SRA is pro-inflammatory or anti-inflammatory. Importantly, as men-
tioned above, the SRA1 gene encodes both coding and noncoding
transcripts. Therefore, it is unclear whether the effects of these
in vitro and in vivo loss of function (LOF) and gain of function (GOF)
studies were mediated by the lncRNA alone. These contradictions
highlight the challenges of replicating in vitro effects within in vivo
models, and certainly, more research is required to tease out the spe-
cific functionality of the lncRNA. Despite this, it is evident in both
studies that SRA1 has a fundamental role in insulin-regulated glucose
metabolism and inflammation. Additionally, SRA1 has great therapeu-
tic potential with strategies already being investigated within the can-
cer and cardiovascular field.48
The antisense noncoding RNA in the INK4 locus, ANRIL, is
expressed from the 9p21 locus, which is frequently mutated con-
taining several diabetes-associated and age-related disease polymor-
phisms.51,52 ANRIL interacts with both polycomb repressive
complexes (PRCs) binding the PRC2 component SUZ12 and PRC1
through polycomb component chromobox 7 (CBX7) forming
ribonucleoprotein complexes, which are required for epigenetic gene
regulation through trimethylation of histone H3 on lysine 27.53,54
Regulation of CpG methylation sites within the promoter of ANRIL is
reported to influence adiposity. Lillycrop et al. discovered that lower
CpG methylation marks in the ANRIL promoter in umbilical cord tissue
at birth was a predictor of increased adiposity in childhood.52 The
ANRIL promoter in subcutaneous AT of adults with obesity also has
reduced methylation, compared with those who are lean.52 Addition-
ally, ANRIL is reportedly induced by high glucose and diabetes in reti-
nal endothelial cell lines.55 Although there is limited knowledge in the
context of adiposity, ANRIL's role in inflammation is well developed,
and its expression is positively correlated with pro-inflammatory fac-
tors. In human endothelial cells, ANRIL is regulated by NF-κB-
meditated TNFα, which induces ANRIL expression. Inflammatory
markers were dysregulated on silencing of ANRIL, which was shown
to be necessary in YY1 transcriptional regulation at the IL-6 and IL-8
promoters.56 Given that ANRIL expression correlates with obesity and
diabetes, as well as its sensitivity to glucose and TNFα, together with
its influence on downstream inflammatory factors, ANRIL may also
have a contributing role in obesity-associated inflammation, which
remains to be fully investigated.
Degirmenci et al. identified 343 lncRNAs in adipocytes that
responded to insulin stimulation of which 80 were superenhancer
lncRNAs involved in energy metabolism.57 Enhancer RNAs are
thought to be important for recruitment of RNA polymerases to the
promoter of neighbouring genes and to influence the three-
dimensional architecture of DNA and chromatin–chromatin interac-
tions (Figure 2).58 It is believed these enhancer RNAs may facilitate
and stabilize chromatin loops acting as tethers that allow them to
influence genes in cis on the same chromosome as well as on other
chromosomes in trans (Figure 2A,B). The adipose-specific insulin
responsive lncRNA (lncASIR) was identified as one such super-
enhancer lncRNA containing several binding sites for PPARγ, an
adipogenesis master regulator. CRISPRi-mediated silencing of lncASIR
resulted in the downregulation of several metabolic pathways down-
stream of insulin signalling including PPAR and adipocytokine signal-
ling as well as lipolysis. Overexpression of this lncRNA was unable to
rescue these effects, suggesting that lncASIR transcription from its
endogenous locus drives its functionality.57 Unfortunately, the study
does not mention the genes under adipocytokine signalling, although
unsurprisingly supplementary data find that leptin is particularly
responsive to insulin, which is important for lipolysis and is also
reportedly regulated by the PPARγ signalling pathway.59
Adiposity-associated inflammation in AT is well correlated with
increased macrophage infiltration. Under lean body conditions or
transient changes in body fat mass, these specialized immune cells
or AT resident macrophages function to regulate tissue homeostasis
and are involved in energy production, adipogenesis and lipid
metabolism.60,61 With obesity, the chronic expansion in AT mass
results in the accumulation of macrophages through monocyte
recruitment as well as proliferation leading to macrophages adopting
a pro-inflammatory activation state that is typically associated with
the development of insulin resistance and accumulation of pro-
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inflammatory cytokines in multiple tissues including the adipose tis-
sue, pancreas, liver and skeletal muscle.60,62 Stapleton et al. found
that AT macrophages from HFD-fed mice suppress the lncRNA
macrophage inflammation-suppressing transcript (MIST). MIST is
located downstream of a lipid chaperon encoded by FABP5 gene,
which has been linked to insulin sensitivity and inflammation.63 LOF
studies reduced FABP5 expression and increased M1-associated
genes, whereas GOF studies found reduction in genes associated
with inflammation and lipid metabolism. RNA pulldown experiments
found that MIST epigenetically regulates pro-inflammatory genes
TNFα, IL-6, IL-10, IL-1β and CCL2 through an interaction with
PARP1. Expression of MIST lncRNA was analysed in human AT
macrophages and was found to be downregulated in individuals
with obesity and negatively correlated with insulin resistance.63
Finally, glucose uptake into skeletal muscle accounts for a sub-
stantial amount of insulin-stimulated glucose uptake from the blood.
To this end, the expression of lncRNAs in skeletal muscle in individ-
uals with increased adiposity and with or without T2D has been
examined, as well as their functional role in mediating skeletal muscle
glucose utilization. H19 is significantly decreased in muscle of human
subjects with obesity and T2D, compared with those who are lean
healthy and have no T2D. Furthermore, H19 depletion results in
impaired insulin signalling and decreased glucose uptake through
phosphatidylinositol-3 kinase (PI3K)/AKT-induced Let-7 miRNA.64
More recently, RNA-seq analysis of skeletal muscle cells has identified
147 differentially expressed lncRNAs that potentially contribute to
palmitic acid-induced insulin resistance.65 Given the importance of
skeletal muscle tissue in glucose utilization and insulin sensitivity,
lncRNAs that have been implicated in mediating changes to skeletal
muscle mass (Section 3.2) may also play important roles in regulating
muscle metabolic function and in turn insulin sensitivity.
3.2 | Sarcopenia and skeletal muscle atrophy
Sarcopenia is the decline of skeletal muscle mass and strength with
age, which is often associated with increased muscle atrophy and
accompanied by an increased systemic inflammatory burden66 and
accumulation of AT.67 Furthermore, it is known that sarcopenia is
more prevalent in persons with increased adiposity.68 This is
believed to be due to the antimyogenic and muscle atrophic activity
of several obesity-associated cytokines and adipokines. Indeed, it
has been shown that obese, but not normal-weight, subcutaneous
AT secretome impairs the myogenesis of old myoblasts.69 Also, AT
in older individuals with increased adiposity secretes differential
amounts of adipokines that can impact the metabolic health and
insulin sensitivity of older skeletal muscle tissue.70 Furthermore,
circulatory levels of TNFα and IL-6 have been shown to be nega-
tively correlated to muscle mass and strength in older individuals,71
and their muscle atrophic actions have been demonstrated in both
in vitro and in vivo studies.72,73 Therefore, the aforementioned
lncRNAs that regulate adiposity and inflammatory cytokines likely
play important roles in mediating obesity-associated sarcopenia. In
addition, several lncRNAs have been directly implicated in the
regulation of skeletal muscle mass.
Currently, no study has investigated the impact of obesity on
human skeletal muscle lncRNA expression. However, evidence that
lncRNA expression can be either influenced by or regulated skeletal
F IGURE 2 Enhancer lncRNAs in cis- and trans-activation of coding gene expression. (A) Enhancer lncRNAs can activate proximal genes in cis
by enhancing and stabilizing DNA looping with neighbouring and remote promoters on the same chromosome. (B) Similarly, spatial organization
of chromosomes within a cell brings together enhancers and trans-located promoters on different chromosomes leading to cis-activation.
(C) Enhancer lncRNAs can also activate coding genes in trans by recruiting transcriptional machinery at distal promoters. lncRNA, long
noncoding RNA
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muscle inflammation with increased adiposity may be inferred from
patients with myositis, a collection of diseases associated with
chronic skeletal muscle inflammation. Using next-generation
sequencing, Hamman et al. identified 1,056 lncRNAs in human skel-
etal muscle, of which 55 and 46 lncRNAs were differentially
expressed in inclusion body and Jo-1 myositis, respectively, com-
pared with skeletal muscle from healthy individuals.74 These differ-
entially expressed lncRNAs included H19 as well as previously
characterized skeletal muscle lncRNAs such as MALAT1, lncMyoD,
PVT1 and MEG3.74–77
In a study by Dey et al., H19 increased miR-675-3p and miR-
675-5p expression in C2C12 cells (a murine myoblast cell line), which
in turn suppressed BMP/TGF-β signalling, promoting differentiation.78
Similar positive regulation of myogenesis has since been observed in
bovine myoblasts, by H19-mediated inhibition of Sirt1/FOXO1 signal-
ling.79 Whether H19 expression is downregulated in human skeletal
muscle from individuals with obesity, as seen in other tissues,64 and in
turn reduces myoblast differentiation has not been investigated,
highlighting the need for further studies to determine the potential
role of H19 in sarcopenia.
Evidence for MALAT1's role in the regulation of skeletal muscle is
conflicting. On the one hand, MALAT1 expression has been demon-
strated to increase during human primary myotube differentiation,
remaining elevated up to Day 6.80 Additionally, MALAT1 knockdown
in C2C12 cells has been associated with a small reduction in myogenin
and reduced proliferation, suggesting that MALAT1 may positively
regulate myogenesis.80–82 In support of this, myostatin, a negative
regulator of muscle mass, was shown to suppress MALAT1 expres-
sion.80 Additionally, in a comprehensive set of experiments, Han et al.
reported that MALAT1 may act as a competitive RNA for miR133. By
binding miRNAs, competitive RNAs can de-repress miRNA target
genes, thus regulating the miRNA activity. Here, this interaction
prevented miR133 from downregulating the transcription factor SRF
in the cytoplasm of C2C12 myoblasts, enabling SRF translocation to
the nucleus and subsequently upregulation of muscle specific gene
expression.81 In contrast, Chen et al. reported that MALAT1 is down-
regulated during the first 24 h of myogenesis and negatively regulated
differentiation, potentially by influencing the transcriptional activity of
MyoD.82 This was demonstrated both in C2C12 and critically in vivo
utilizing MALAT1 knockout mice. However, the potential impact of
increased skeletal muscle MALAT1 expression and its role in regulat-
ing myogenesis in human skeletal muscle linked to increased adiposity
has not been studied. Similarly, numerous other lncRNAs have also
been shown to be directly involved in the regulation of skeletal mus-
cle myogenesis and have recently been reviewed by Sweta et al.83
Future studies investigating the role of such lncRNAs with increased
adiposity and inflammation will also be important in identifying their
potential roles in the regulation of sarcopenia.
Of the lncRNAs that have been associated with muscle ageing,
Gm17281 (also referred to as Chronos) was found to be significantly
increased with age in the skeletal muscle of mice, promoting atrophy
mediated by repression of Bmp7, a positive regulator of hypertrophic
gene expression.84 Critically, a mean 42% increase in myofiber cross
sectional area was observed in vivo following 14 days of siRNA treat-
ment, an effect similar to that seen following myostatin inhibition.84
In contrast, the expression of muscle anabolic regulator 1 (MAR1)
in skeletal muscle declines with age in mice.85 MAR1 was found to be
a sponge for microRNA-487b, identified as a negative regulator of
Wnt5a expression. Lentiviral-mediated overexpression of MAR1 in
C2C12 myoblasts increased expression of Wnt5a and in turn the myo-
genic transcription factors, MyoD, MyoG, Mef2c and Myf5, promoting
differentiation, whereas the reverse was observed following MAR1
knockdown. Similar effects were observed in vivo following the
upregulation or downregulation of MAR1 in adult mice, whereas
MAR1 upregulation in aged (22 months) mice protected against mus-
cular atrophy. Therefore, a decline in MAR1 with age may result in
reduced inhibition of microRNA-487b, negatively impacting myoblast
differentiation and skeletal muscle mass. Together, these studies iden-
tify the potential of age associated lncRNAs as drivers of muscular
atrophy in sarcopenic obesity.
In addition to age, MAR1 was regulated by other external stimuli;
its expression decreased with muscle unloading and was restored with
reloading.85 Other lncRNAs have also been demonstrated to respond
to alterations in load. In a comprehensive study, Hitachi et al. utilized
eight different animal models to investigate the impact of both hyper-
trophy and atrophy on skeletal muscle lncRNA expression.86 Of note,
this study highlighted the varied regulation of lncRNA expression
depending on the type of model used, in addition to identifying Gtl2,
IG-DMR and DUM1 as potentially important lncRNAs mediating
hypertrophy.86 In a similar study, the novel atrophy-related lncRNA-1
(Atrolnc-1) was upregulated in the skeletal muscle of murine models
of muscle wasting.87 Furthermore, Atrolnc-1 was demonstrated to
bind A20 binding inhibitor of NF-κB-1 (ABIN-1) in the cytoplasm of
C2C12 myotubes, impairing its function as an inhibitor of NF-κB. As a
result, Atrolnc-1 appears to facilitate an NF-κB-mediated upregulation
of MuRF-1 expression, resulting in increased proteolysis. In support of
these in vitro findings, Atrolnc-1 knockout mice exhibit skeletal mus-
cle hypertrophy, whereas overexpression results in atrophy, again
associated with upregulated MuRF-1 expression.87 As sarcopenia is
associated with skeletal muscle unloading, understanding the regula-
tion of human skeletal muscle lncRNA expression in this setting is
critical.88
It is also important to consider that human skeletal muscle is
composed of multiple different fibre types that can be classified as
either type I (slow twitch) or type II (fast twitch) based, in part, on
their myosin heavy chain (MHC) expression. Owing to the plastic
nature of skeletal muscle, fibre types can shift in response to regular
training and disease. For example, elderly individuals with sarcopenia
primarily present with a loss of type II fibres, whereas chronic obe-
sity is primarily associated with type I fibre atrophy. Recently, a
number of studies have investigated the potential role of lncRNAs in
the regulation of muscle fibre type89–92 and have been associated
with a switch in MHC expression from IIx to IIa in humans following
a 5-week exercise protocol.92 Thus, it will be important to identify
if similar lncRNA-mediated changes in fibre type occur in the
obese state.
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3.3 | Osteoarthritis
Obesity-mediated chronic low-grade inflammation is associated with
dysregulated innate immune system activity. The innate immune sys-
tem is the first line of defence utilizing leukocytes, which recognize
pathogen or damage-associated molecular patterns and activate a
cascade of pro-inflammatory pathways through pattern-recognition
receptors.93,94 Leukocytes secrete pro-inflammatory cytokines, which
further promotes the pro-inflammatory secretory environment
leading to increases in TNFα, IL-1β, IL-6, IL-8, leptin and growth
hormone.95 Critically, there is now increasing evidence that lncRNAs
are central mediators of the innate immune response, and therefore,
their role in adiposity-related inflammatory conditions such as osteo-
arthritis (OA) and rheumatoid arthritis (RA)94–96 is being further
studied.
Low-grade inflammatory assaults in OA are central to joint
deterioration, with synovial fluid leukocyte counts in knee
osteoarthritis correlating with synovial membrane inflammation
(synovitis).97 Additionally, synovitis is exacerbated in patients with
OA and increased adiposity, where obese OA synovial fibroblasts
(OASF) secrete greater amounts of IL-6 and IL-8 adding to the local
inflammatory joint environment.98 These obese OASFs are highly
proliferative and exhibit an inflammatory phenotype that consists of
several long intergenic noncoding RNAs. Nanus et al. reported
19 differentially expressed lncRNAs in OA synovial
fibroblasts isolated from end-stage OA patients with obesity
compared with those who were lean and without OA.98 Expression
of seven lncRNAs, MALAT1, CARMN, AF131217.1, miR155HG,
LINC01705, RP11-863p13.3 and RP11-367F23.2, was induced in
OASF in response to stimulation with obesity-associated cytokines
including IL-1β, TNFα, leptin and visfatin. Interestingly, proliferation
of obese OASF and the expression of IL-6 and IL-8 were reduced in
MALAT1 LOF studies. Other studies have found that this lncRNA
specifically interacts with and influences the distribution of pre-
mRNA splicing factors to nuclear speckles, and its depletion results
in cell cycle arrest and activation of p53 and its targets.99 Similarly,
pathway analysis of RNA-sequencing data following MALAT1
knockdown in OASF confirmed downregulation of cell proliferation
and inflammatory genes, also supporting the therapeutic potential of
MALAT1.98 PACER, CILinc01 and CILinc02 (IL7-AS) are another
three lncRNAs reported by the same group, which respond to pro-
inflammatory cytokine stimuli in OA chondrocytes. Pearson et al.
reported that CILinc01 and CILinc02 knockdown followed by IL-1β
induction resulted in increased expression of IL-6, IL-8 and TNFα.100
Additionally, Roux et al. identified 242 novel lncRNAs in
chondrocytes, including IL7-AS, whose expression changed following
the induction of the innate immune response.94 Interestingly, H19 is
prominently expressed in both OA and RA synovial tissue fibroblasts
and macrophages. Serum starvation and stimulation with or without
IL-1β, TNFα or PDGF-BB reportedly induce H19 expression in
synovial fibroblasts via the MAPK/ERK/PI3K pathways.101 H19
sensitivity to cytokine stimulation and serum starvation is thought
to be important for synovial tissue dedifferentiation, ongoing
inflammation and oxidative stress. Several studies in the last 2 years
report inflammation-associated lncRNAs in osteoarthritis including
PVT1,102 DANCR,103 XIST,104 H19,105 FOXD2-AS1106 and
MFI2-AS1.107 Although these studies do not focus on adiposity, the
implication of lncRNAs in OA is clear, and given that the
majority of OA patients have significantly increased levels of
adiposity, further investigations may help stratify patients for
specific diagnostics and therapies.
3.4 | Rheumatoid arthritis
RA is a chronic inflammatory autoimmune disease where abdominal
adiposity is prevalent amongst 20%–50% of patients.108 Immune
dysfunction in RA leads to destruction of bone and cartilage, immune
cell infiltration and inflammation.109 Several lncRNAs have been
recognized to influence inflammatory pathways such as NF-κB signal-
ling, p38 MAPK and toll-like receptor pathways in RA.109 Although
the precise mechanisms are poorly defined, especially in the context
of obesity, the epigenetic regulation of the synovial RA fibroblast
phenotype is considered to be central in mediating the inflammatory
and autoimmunity RA joint pathology.110
Unsurprisingly, MALAT1 has also been identified to regulate
synovial fibroblast proliferation and inflammation in RA. In RA
synovial tissue, MALAT1 expression is found to be downregulated.
Additionally, in contrast to the previously detailed findings in OA,
silencing of MALAT1 in RA fibroblast-like synoviocytes (FLSs) results
in an increase in IL-6, IL-10 and TNFα secretion and elevated prolifer-
ation.111 Li et al. found that MALAT1 binds to the promoter of
CTNNB1 regulating DNA methylation to inhibit β-catenin and thus
the Wnt-signalling pathway.
The pro-adipogenic lncRNAs HOTAIR has also been implicated in
RA. HOTAIR is expressed from the HOXC gene cluster on chromo-
some 12 and selectively binds components of the PRC2 complex
including the histone methyltransferase EZH2.12 Whereas the 50
region of HOTAIR associates with PRC2 proteins, the 30 domain also
has been found to interact with the histone demethylase complex
LSD1/CoREST/REST.13 HOTAIR expression is elevated in adipose-
derived exosomes in individuals with obesity and is also reported in
RA serum exosomes.112,113 In RA, profiling of exosomal lncRNAs iden-
tified several differentially expressed lncRNAs including HOTAIR,
MEG9, SNHG4, TUG1, NEAT1, MALAT1 and SNHG1. HOTAIR
expression was found to be increased fourfold in obese RA exosomes,
compared with healthy controls. Exosomal HOTAIR contributed to
the migration and activation of macrophages as well as the production
of matrix metalloproteinases.113 Exosomes from adipose-derived
mesenchymal stem cells are also of therapeutic interest in OA.114
Exosomes isolated from serum and synovial fluid of patients with OA
contain HOTAIR, GAS5 and PCGEM1 lncRNA transcripts, although
HOTAIR and GAS5 were not significantly different compared to
prearthritic controls.115 However, as those patients who were
prearthritic controls had also presented with incidental knee pain, it is
difficult to dissect the functional significance of HOTAIR in the
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context of OA. The exact implications of HOTAIR in adipose-derived
exosomes in both RA and OA have yet to be fully explored especially
with the added complexity of obesity.
4 | LncRNA CHALLENGES AND CLINICAL
PROSPECTS
In the context of obesity-associated inflammation, it will be important
to distinguish between lncRNAs that are simply associated with
increased adiposity and those that are implicated in mediating a
chronic low-grade inflammatory obese state, particularly as lncRNAs
have the potential to be the next generation of biomarkers and thera-
peutic targets owing to their tissue-specific nature of expression.116
However, the functional study of lncRNAs is not without its chal-
lenges. Owing to their poor primary sequence conservation across
species, in vivo GOF and LOF studies can be nonpredictive. However,
in some cases, it is thought that lncRNA functional conservation is
geared towards the maintenance of genomic position (synteny) rather
than the transcript itself.94,117,118 Importantly, it has been reported
that around 10% of human lncRNAs associated with the innate
immune inflammatory response have syntenic versions in the
mouse.74 Therefore, a future focus on syntenic lncRNAs, such as the
aforementioned IL7-AS,94 would give the greatest opportunity for
in vivo validation studies to translate to humans, alongside LOF stud-
ies in primary human cells.
Clinical trials involving lncRNAs are largely diagnostic and pre-
dominantly in the cancer field, where lncRNAs are being examined as
biomarkers of disease state or prognostic markers. To date, PCA3 is
the only lncRNA to have gained biomarker approval from the Food
and Drug Administration for detecting human prostate cancer.119,120
The length of lncRNA sequences and their complex secondary and
tertiary structures have added complexity to pharmacological
approaches where much is yet to be determined.121 However, in
recent years, drug classes have broadened to include RNAi-based
therapeutics, many of which show great promise having reached pre-
clinical stages for some cancer lncRNA-targeted therapeutics.120
Many of these RNAi approaches have been demonstrated in animal
models against protein-coding targets and include locked nucleic acid
GapmeRs (LNA) and antisense oligonucleotides (ASO) technologies,
although siRNA approaches have proven to be most successful owing
to their gene targeting efficacy in cancer preclinical trials.122 There-
fore, many of the lncRNAs mentioned in this review could provide a
new class of targets for RNAi-based therapeutics.
Additionally, lifestyle changes including dietary interventions and
exercise have long been advocated as measures to tackle the effects
of adiposity on age-related inflammatory conditions. Indeed, lncRNAs
linked to weight loss, which show promising mechanistic relevance,
have been identified such as lncRNA-p19461.29 Coupling both life-
style changes and targeting of lncRNAs in various obesity-associated
inflammatory conditions may be of therapeutic benefit. Furthermore,
determining their mode of action and understanding the lncRNA com-
monalities that regulate obesity-related inflammatory processes
across different conditions could identify lncRNA-mediated targets
that are suitable for therapeutic intervention.
5 | CONCLUSION
Our understanding of the role of lncRNAs in mediating obesity-
associated inflammatory disease is very much in its infancy. However,
a growing number of lncRNAs have been identified as differentially
expressed in the obese state, and several have been implicated as reg-
ulators of AT and skeletal muscle mass and obesity-associated inflam-
matory pathways. Therefore, determining the mode of action of these
disease-associated lncRNAs will be insightful and potentially clinically
relevant, as will more extensive tissue expression profiling in humans
to fully determine their functional roles.
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